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HISTORICAL
IN the early 1920's when crude extracts of pancreas were used as the source of
insulin for animal experiments, it was noted that a transient rise in blood sugar
often occurred before the expected insulin hypoglycaemia. The effect was at first
wrongly attributed to adrenaline but soon the presence of a hitherto unknown
hyperglycaemic agent was suspected.
Glucagon, the fraction responsible for the hyperglycaemia, was isolated by
Collens and Murlin in 1929. However, it was not until the 1950's, following the
introduction of new electrophoretic and chromatographic techniques that glucagon
was obtained in sufficiently pure form to allow chemical characterization (Staub,
Sinn and Behrens, 1953). Porcine glucagon was shown to be a single chain poly-
peptide of 29 amino acids with molecular weight 3485 (Bromer, Sinn and Behrens,
1957). Subsequently immunofluorescent techniques revealed that the alpha cells of
the pancreatic islets were its source (Baum, Simons, Unger and Madison, 1962).
The glucagon molecule shows a striking similarity to the secretin molecule
chemically and shares some biological properties with it. Secretin is composed of
27 amino acids. Starting from the N-terminus 14 positions are occupied by the
same amino acids. Under certain conditions both hormones can stimulate lipolysis
and insulin secretion.
PHYSIOLOGY
Following secretion from the pancreas glucagon is either degraded by proteolytic
enzymes in the plasma (Eisentraut, Whissen and Unger, 1968) or metabolised and
cleared by the liver (Buchanan et al, 1968) and kidneys (Lefebvre, Luyckx and
Nizet, 1974). Degraded hormone has no biological activity. At present little is
known about the physiological factors controlling rate of breakdown and clearance
of the hormone.
Regulation of glucagon secretion by changes in plasma glucose appears to be as
sensitive as regulation of insulin secretion by this means. Hypoglycaemia induced
by insulin (Ohneda et al, 1969; Gerich et al, 1974c), by a sulphonylurea (Buchanan
et al, 1969) or by starvation (Aguilar-Parada et al, 1969) is associated with a rise in
glucagon levels while hyperglycaemia causes a fall in the level (Unger et al, 1970).
More recently glucagon has been shown to have a role in the maintenance of blood
sugar during overnight fasting (Alford et al, 1974; Gerich et al, 1975). In the liver
65glucagon stimulates glycogenolysis and gluconeogenesis while inhibiting glycogen
synthesis; these changes being associated with a rise in hepatocyte cyclic 31, 51.
adenosine monophosphate (cAMP) level.
Aminoacids stimulate both insulin and glucagon secretion, the rise in glucagon
serves to limit the fall in glucose that would occur if insulin alone was secreted
after a mainly protein meal (Unger et al, 1969). The aminogenic glucagon response
is abolished by hyperglycaemia (Muller et al, 1970) but where there has been
prolonged dietary carbohydrate restriction there is a brisk aminogenic glucagon
response from an already elevated basal glucagon level (Muller et al, 1971a).
Glucagon can cause lipolysis in rat (Hagen 1961) and avian (Langslow & Hales,
1970) adipose tissue and triglyceride breakdown in perfused rat liver (Penhos et al,
1966). However, it has been difficult to show a lipolytic effect of glucagon at
physiological levels in man. Supraphysiological levels have lipolytic and ketogenic
effects in the human (Liljenquist et al, 1974). Free fatty acid (FFA) levels and
glucagon levels have an inverse relationship in humans (Gerich et al, 1974a) and
dogs (Luyckx and Lefebvre, 1969). However, in man should hyperglycaemia coexist
with very low FFA levels the effect of glucose on glucagon secretion will pre-
dominate (Gerich et al, 1974). Absorption of a fat meal leading to a rise in plasma
triglyceride (TG) level causes no change in plasma glucagon level in humans but is
associated with a rise in dogs. In dogs, infused TG causes no glucagon rise and it
has been postulated that an enteric signal such as pancreozymin may be responsible
for the hyperglucagonaemia following a fat meal (B6ttger et al, 1973). At pharma-
cological levels glucagon will lower plasma TG levels (Eaton, 1973) but this effect
has not yet been shown at physiological levels of the hormone.
Glucagon at physiological concentrations stimulates insulin release (Ketterer et al,
1967). The insulinogenic and hyper glycaemic properties of glucagon are indepen-
dent, the former probably being important for insulin-dependent glucose meta-
bolism in peripheral tissues during times of starvation or low carbohydrate intake.
Insulin exerts a strong influence over glucagon secretion. High glucagon levels
found in experimental insulin deficiency in dogs are promptly lowered by insulin
administration (Muller et al, 1971b). Similarly when insulin-deficient isolated pan-
creatic islets were incubated in high glucose media glucagon secretion was sup-
pressed only after addition of insulin (Buchanan and Mawhinney, 1973).
Although glucagon at pharmacological levels can cause catecholamine release
(Sarcione et al, 1963; Sheps and Maher, 1968) this seems not to occur at physio-
logical levels (Broadus et al, 1970). Glucagon secretion rises abruptly under acute
stress (Bloom, 1973) and during adrenaline infusion (Gerich, Karam and Forsham,
1973). It is now clear that the autonomic nervous system, especially the parasym-
pathetic is important in mediating the glucagon response to hypoglycaemia (Bloom,
Edwards and Vaughan, 1974) and in man following truncal vagotomy this response
is very poor (Bloom, Vaughan, Russell, 1974).
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levels of glucagon, a fuel mobilizer, rise too. This response can be blocked by
propranolol pretreatment (Luyckx and Lefebvre, 1974) and is probably dependent
on the sympathetic nervous system.
Food (or its absorption products) and the autonomic nervous system seem to
have major roles in the control of glucagon secretion. Secretion can be modified by
substances which change the intracellular cAMP level (Marco et al, 1973) or
destroy the microtubular apparatus of the alpha cell (Leclercq-Meyer et al, 1974;
Edwards, 1973). Potassium imbalance modifies secretion (Kuzuya et al, 1974; San-
teusanio et al, 1973). Whereas it has been clearly shown that low calcium levels
cause decreased insulin secretion either under experimental conditions (Grodsky
and Bennett, 1966) or in man (Laron and Rosenberg, 1970), the role of calcium in
glucagon secretion remains controversial (Leclercq-Meyer et al, 1973; Gerich et al,
1974b).
Somatostatin is a tetradecapeptide isolated from the hypothalamus. Recently it
has been found in the D cells of pancreatic islets. Somatostatin (growth hormone
release inhibiting factor) inhibits the release of both insulin and glucagon.
Other actions of glucagon possibly only of pharmacological importance are
augmented urinary excretion of sodium, potassium, calcium, phosphate and mag-
nesium (Birge and Avioli, 1969), positive inotropism on the myocardium (Parmley
et al, 1968), inhibition of gastric motility (Necheles et al, 19i66) and stimulation of
growth hormone release (Mitchell et al, 1969).
MEASUREMENT OF GLUCAGON
Attempts at precise measurement of circulating levels of pancreatic glucagon have
met with many technical problems. Circulating levels are low and radioimmuno-
assay has been the method of choice. One of the important basic needs for a sen-
sitive and precise radioimmunoassay is an antibody with high specificity for the
hormone (or antigen) being measured. Experienced workers have found that most
antibodies raised to purified glucagon of pancreatic origin will cross-react with a
number of polypeptides from the gastrointestinal tract. These peptides are as yet
poorly characterized and their relationships to pancreatic glucagon remain obscure.
A few antibodies have been found which show little cross-reactivity with these gut
peptides.
Measurements of plasma 'glucagon' levels with such antibodies have been used
to define the physiological circulating levels of glucagon. Such an antibody was first
discovered in 1968 (Eisentraut et al, 1968); since then a great deal of work has been
done to define glucagon's role in health and disease. In the resting, non-stressed
state in normal individual;s the peripheral venous level falls in the range 40-200
pg/ml; the portal venous level is several times greater.
67CLINICAL SYNDROMES IN WHICH GLUCAGON IS, OR MAY BE, IMPORTANT
(a) Glucagonoma syndrome
The most convincing evidence that elevated glucagon levels, in the presence of
normal insulin secretion, can cause the diabetic syndrome comes from a single case
report. Lightman and Bloom (1974) have reported the return of completely normal
glucose tolerance in a previously insulin-dependent diabetic following the removal
of a glucagonoma.
Glucagonomas are tumours of the pancreatic alpha cells found in patients who
have often presented at dermatology clinics with a striking necrolytic, migratory
erythematous rash, usually affecting the lower trunk and groin areas. In addition
to the rash there is stomatitis, carbohydrate intolerance (usually mild), anaemia
and a history of weight loss (Mallinson et al, 1974). Hypoaminoacidaemia is often
present as well as the high plasma glucose and the diagnostic high plasma glucagon
levels. The high plasma glucagon levels are of aetiological importance in the
development of the diabetic state.
(b) Idiopathic diabetes mellitus
Glucagonomas are rare and the role played by glucagon in the aetiology of
idiopathic diabetes mellitus is not as fully understood. In the complex biochemical
situation occurring in diabetes it may be difficult to decide which abnormalities are
primary and possibly of aetiological importance and which occur as a consequence
of the diabetic state. It is generally agreed that pathophysiological changes which
occur early in the course of a genetic disease are more closely related to the primary
disorder than are those which occur later. Since genetic factors are important in the
development of diabetes, assessment of persons supposed to be at high risk of
developing the disease has always been an area of active investigation. For example,
it has been shown that otherwise healthy monozygotic twin sibs of diabetic patients
may have decreased and delayed insulin responses to glucose infusion (Cerasi and
Luft, 1967). Day and Tattersall (1975) doing a similar study, found that the mean
glucagon levels in the unaffected twins tended to be higher than in other healthy
control subjects. This would support the concept that in idopathic diabetes mellitus
there may be an inherited abnormality of glucagon secretion or metabolism as well
as a primary abnormality of insulin secretion.
In established idiopathic diabetes several abnormalities of glucagon secretion have
been reported. There is relative or absolute basal hyper-glucagonaemia (Unger et al,
1970; Muller et al, 1970; Buchanan and McCarroll, 1972; Wise et al, 1973a).
Ingested or infused glucose has been reported to cause no suppression or even
paradoxical rise in glucagon levels (Muller et al, 1970; Buchanan and McCarroll,
1972).
Although in experimental insulin deficiency the alpha cell unresponsiveness to
hyperglycaemia is promptly reversed by administration of insulin (see above) in the
human diabetic this unresponsiveness is not fully corrected even by massive doses
of insulin (Unger et al, 1972) suggesting that there is some other (perhaps primary)
abnormality of the alpha cell in this condition.
68Whereas in normal individuals there is a striking rise in glucagon level in response
to hypoglycaemia, this response was absent in a group of insulin-dependent dia-
betics where hypoglycaemia was produced by insulin (Gerich et al, 1973a). This
finding again suggests an intrinsic alpha cell abnormality in diabetes. Aminogenic
glucagon secretion is exaggerated in diabetics despite hyperglycaemia which in non-
diabetics abolishes the aminogenic stimulus (Unger et al, 1970; Muller et al, 1970;
Wise et al, 1973a).
For some time it has been known that very high levels of glucagon may occur in
diabetic ketoacidosis (Assan et al, 1969; Unger et al, 1970). Recently Gerich and
coworkers (1975) have shown that glucagon had aetiological importance in the
development of the ketoacidotic state. When they withheld insulin from a group of
insulin-dependent diabetics there was a prompt rise in plasma glucagon, glucose
and ketone levels. In the same diabetics if glucagon secretion was blocked (by in-
fusion of somatostatin) at the same time as insulin was withheld then plasma glucose
rose slowly and ketone levels rose very little over the time period studied (18
hours).
In idiopathic diabetes there is, therefore, some evidence of primary alpha cell
abnormalities. In established cases relative or absolute hyperglucagonaemia con-
tributes to the hyper glycaemia and glucagon probably plays a key role in develop-
ment of diabetic ketoacidosis.
Do glucagon levels change with diabetic management and control? In a large
group of mild maturity-onset diabetics treated by dietary methods only, there was
very little change in glucagon levels after six months' treatment which resulted in
significant improvement both in the glucose tolerance and insulin secretion on
glucose challenge. (Care was taken to ensure a similar carbohydrate intake for one
week before the initial GTT and the test carried out at six months), (Trimble, 1975).
It has been mentioned above that high glucagon levels associated with ketoacid-
osis do tend to drop with insulin treatment, however, there is no evidence that the
alpha cell responsiveness to glucose is ever fully restored. Unger and coworkers
(Unger et al, 1970) found that the glucagon response to arginine was exaggerated
and unrelated to duration of diabetes, body weight, or type of diabetic treatment
(the diabetic group included juvenile and maturity-onset types and treatment was
either by insulin, sulphonylureas or diet alone).
There are contradictory reports in the literature about the effect of sulphony-
lureas on glucagon secretion. Suppression (Samols et al, 1969), non-suppression
(Pek et al, 1972) and stimulation (Harrison and Samols, 1975) have been recorded.
It would appear that sulphonylureas may lower glucagon levels if they are already
raised by the stimulus of hypoglycaemia. However, it cannot be inferred from the
above publications that this is a primary effect on the alpha cell; it may be second-
ary to the effect of the sulphonylurea-induced insulin secretion on the alpha cell.
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The kidneys and liver are the important sites of glucagon breakdown and clear-
ance. There is a high incidence of carbohydrate intolerance in renal and liver failure.
Hyperglucagonaemia has been reported in uraemia (Assan, 1972; Bilbrey et al,
1974). Since the hyperglucagonaemia of renal failure may occur early on and in the
absence of glucose intolerance (Trimble, McEvoy and Buchanan, unpublished
data) it may be of aetiological importance in the development of diabetes in this
situation.
High levels of glucagon have also been found in cirrhosis (Marco et al, 1973).
However, if liver glycogen stores are poor it is less likely that glucagon plays any
role in the development of hyperglycaemia in this situation.
(d) Other endocrine disorders
High glucagon levels occur in Cushing's syndrome (Wise et al, 1973b) and myxo-
edema but not thyrotoxicosis (Seino et al, 1974). In acromegaly the levels have been
reported on as being slightly elevated (Lawrence, 1972) but this could not be con-
firmed by others (Trimble, 1975).
Adrenaline increases glucagon and decreases insulin secretion, both of these
changes probably contribute to the glucose intolerance seen in situations associated
with raised catecholamine levels.
The stress reaction may be implicated in the hyperglucagonaemia seen in cases
of trauma (Meguid et al, 1972), burns (Wilmore et al, 1974), severe infections
(Rocha et al, 1973) and coronary thrombosis (Willerson et al, 1973).
(e) Obesity
Stimulated glucagon output has been reported as decreased (Wise et al, 1973a)
or increased (Gossain et al, 1974; Gerich, Langlois, Noacco, 1973) in obesity. At
present it is doubtful whether glucagon is important in the carbohydrate intolerance
associated with obesity.
(f} Primary endogenous hypertriglyceridaemia
In many patients with primary endogenous hypertriglyceridaemia the glucagon
levels are high. Eaton and Schades (1973) have postulated that there is resistance to
the triglyceride lowering action of glucagon in this situation.
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In chronic pancreatitis the glucagon and insulin response to arginine infusion falls
into two patterns. In one group of individuals there may be a concomitant decrease
in glucagon and insulin secretion while the other group which includes those with
severe insulinopenia show relative hyperglucagonaemia (Kalk et al, 1974). In cystic
fibrosis Stahl and coworkers (1974) found that there was a tendency for stimulated
glucagon output to be decreased by about the same amount as was insulin secretion.
However, others have found high, 'normal', and low aminogenic glucagon secretion
in patients with cystic fibrosis (Redmond, Buchanan and Trimble; in preparation).
High levels of glucagon in this series were found in those with most severe pul-
monary involvement. Late in the disease extensive pancreatic fibrosis could theor-
etically limit both insulin and glucagon secretion, earlier on other factors such as
stress and bacterial infections may be important.
In acute pancreatitis mild elevations of glucagon have been reported but in the
more severe cases glucagon levels have been reported as low (Day et al, 1972).
SUMMARY
Although it has been known for a long time that glucagon has many powerful
biological activities in the in vitro situation the importance of glucagon has always
been overshadowed by that of insulin because of difficulty in proving that its actions
are significant at physiological circulating levels in the intact human. The develop-
ment of (relatively) specific assay systems for its measurement has led to many
advances in our understanding of the hormone. If any other single item can be
picked as having made an outstanding contribution to our knowledge of the physio-
logical importance of the hormone it has been the experimental use of the hormone
somatostatin. Glucagon and insulin often act as a bihormonal unit, there being few
situations in which changes in the level of one is not accompanied by changes in
the level of the other. Consequently, biological effects noted have been due to the
sum of glucagon and insulin activities. By the use of somatostatin the endogenous
secretion of both can be blocked and the biological effects of infused glucagon can
be observed. Unfortunately, somatostatin has side effects which will probably pre-
clude its further use in humans. However, there is unequivocal evidence that gluca-
gon is a hormone with significant physiological activity and that it is also of
importance in many common clinical syndromes.
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